1. Home
  2. VNRX

as of 12-02-2025 4:00pm EST

$0.30
+$0.01
+2.47%
Stocks Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances Nasdaq

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Chart Type:
Time Range:
Founded: N/A Country:
United States
United States
Employees: N/A City: HENDERSON
Market Cap: 40.8M IPO Year: N/A
Target Price: $3.17 AVG Volume (30 days): 2.5M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.23 EPS Growth: N/A
52 Week Low/High: $0.29 - $0.94 Next Earning Date: 11-13-2025
Revenue: $1,472,007 Revenue Growth: 14.48%
Revenue Growth (this year): 324.32% Revenue Growth (next year): 247.82%

AI-Powered VNRX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 73.47%
73.47%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest VolitionRX Limited News

VNRX Breaking Stock News: Dive into VNRX Ticker-Specific Updates for Smart Investing

All VNRX News

Share on Social Networks: